Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation
Innate immunity is involved in the biology of graft versus host disease and common airway diseases. We screened 15 genes in this pathway using a linkage disequilibrium-based approach to identify potential candidate genes that may be involved in the development of airflow obstruction after hematopoie...
Saved in:
Published in | Blood Vol. 107; no. 5; pp. 2200 - 2207 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Elsevier Inc
01.03.2006
The Americain Society of Hematology 2006 by The American Society of Hematology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Innate immunity is involved in the biology of graft versus host disease and common airway diseases. We screened 15 genes in this pathway using a linkage disequilibrium-based approach to identify potential candidate genes that may be involved in the development of airflow obstruction after hematopoietic cell transplantation. Sixty-nine single-nucleotide polymorphisms were selected for assessment in a discovery cohort (n = 363). Significant associations were validated in a validation cohort (n = 209). Expression of the candidate gene was demonstrated by detecting gene transcript and protein in malignant and normal small airway epithelial cells. In the discovery cohort, 133 patients developed significant airflow decline. Four patient and donor bactericidal/permeability-increasing (BPI) haplotypes were associated with a 2-fold to 3-fold increased risk of developing significant airflow decline (P values, .004-.038). This association was confirmed in the validation cohort, which had 66 patients with significant airflow decline, with 9 significant haplotypes (P values, .013-.043). BPI gene transcript and protein were detected in airway epithelial cells. These results suggest mutations in the BPI gene significantly influence the risk of developing rapid airflow decline after hematopoietic cell transplantation and may represent a novel therapeutic target for this form of airway disease. |
---|---|
Bibliography: | The online version of this article contains a data supplement. Supported by National Institutes of Health (NIH) grants HL71914, CA18029, CA15704, CA106320, AI33484, K23HL69860, an American Lung Association of Washington Research Grant, and the Amy Strelzer Manasevit Research Award from the National Marrow Donor Program. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734. Prepublished online as Blood First Edition Paper, November 22, 2005; DOI 10.1182/blood-2005-06-2338. Reprints: Jason W. Chien, Pulmonary and Critical Care Section, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, D5-280, Seattle, WA 98109-1024; e-mail: jchien@fhcrc.org. |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2005-06-2338 |